Ausgewählte Publikationen
Hier sind einige ausgewählte, wissenschaftliche Arbeiten gelistet.
Weitere Publikationen finden Sie in der
National Library of Medicine
PubMed
unter
Brockhoff G
und/oder
Wege AK
Publikationen
-
Brockhoff G & Wege AKListenelement Nr. 1
Schweihofer V, Schulz D, Blazquez R, Brockhoff G, Ettl T, Fiedler M, Heimer S, Schikora J, Bauer RJ, Wege AK. Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. Front Oncol. 2025 Aug 8;15:1622008.
Goerg AM, Piendl G, Albert V, Ortmann O, Wege AK, Brockhoff G: Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. BMC Cancer BMC Cancer. 2025 Jun 1;25(1):978.
Schweihofer V, Bruss C, Seitz S, Glehr G, Hetterich M, Weber F, Hatzipanagiotou M, Álvarez MF, Ortmann O, Brockhoff G, Bauer RJ, Wege AK. Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy. Cancer Cell Int. 2025 Mar 27;25(1):120.
Albert V, Bruss C, Tümen D, Piendl G, Weber F, Dahl E, Seitz S, Ortmann O, Wege AK, Brockhoff G: HER4 expression in MCF-7, T-47D, and ZR-75-1 breast cancer cells differentially affects the sensitivity to tamoxifen and abemaciclib treatment and restricts MCF-7 tumor growth in humanized tumor mice. Int J Mol Sci. 2024 Jul 8;25(13):7475.
Bruss C, Albert V, Seitz S, Blaimer S, Kellner K, Pohl F, Ortmann O, Brockhoff G*, Wege AK*. Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative-specific breast cancer based Humanized Tumor Mice (HTM) enhances anti-PD-L1 treatment efficacy. Front Immunol. 2024 Apr 29;15:1355130..
* = co-senior-authorship
Bruss C, Kellner K, Albert V, Hutchinson JA, Seitz S, Ortmann O, Brockhoff G, Wege AK. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion. Cancers (Basel). 2023 May 4;15(9):2615.
Bruss C, Kellner K, Ortmann O, Seitz S, Brockhoff G, Hutchinson JA, Wege AK. Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. Cancers (Basel). 2022 Apr 28;14(9):2214.
Albert V, Piendl G, Yousseff D, Lammert H, Hummel M, Jagla W, Gaumann A, Wege AK, Brockhoff G: Protein kinase C targeting of luminal (T47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects. Arch Gynecol Obstet. 2022 Oct;306(4):1197-1210.
Wege AK, Rom-Jurek EM, Jank P, Denkert C, Trumpp A, Ugocsai P, Solbach C, Blohmer JU, Sinn B, van Mackelenbergh M, Möbus V, Tumpp, A, Marangoni E, Pfarr N, Irlbeck C, Warfsmann J, Polzer B, Ortmann O, Loibl S, Vladimirova V, Brockhoff G. mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. Int J Cancer. 2022 Apr 15;150(8):1357-1372.
Wege AK, Dreyer TF, Teoman A, Ortmann O, Brockhoff G, Bronger H. CX3CL1 Overexpression prevents the formation of lung metastases in trastuzumab‐treated MDA‐MB‐453‐based humanized tumor mice (HTM). Cancers (Basel). 2021 May 18;13(10):2459.
Wege AK, Kirchhammer N, Kazandjian LV, Prassl S, Brandt M, Piendl G, Ortmann O, Fischer S, Brockhoff G. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM). J Transl Med. 2020 Aug 15;18(1):316.
Wege AK, Chittka D, Buchholz S, Klinkhammer-Schalke M, Diermeier-Daucher S, Zeman F, Ortmann O, Brockhoff G. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women. Breast Cancer Res. 2018 Nov 20;20(1):139.
Brockhoff G, Seitz S, Weber F, Zeman F, Klinkhammer-Schalke M, Ortmann O, Wege AK. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget. 2017 Dec 27;9(5):6201-6212.
Rom-Jurek EM, Kirchhammer N, Ugocsai P, Ortmann O, Wege AK, Brockhoff G. Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. Int J Mol Sci. 2018 Feb 13;19(2):563.
Wege AK, Weber F, Kroemer A, Ortmann O, Nimmerjahn F, Brockhoff G. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget. 2017 Jan 10;8(2):2731-2744.
Huber S, Wege AK, Bernhardt G, Buschauer A, Brockhoff G. Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Cytometry A. 2015 Aug;87(8):707-16.
Wege AK, Schmidt M, Ueberham E, Ponnath M, Ortmann O, Brockhoff G, Lehmann J. Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies. MAbs. 2014 Jul-Aug;6(4):968-77.
Wege AK, Schardt K, Schaefer S, Kroemer A, Brockhoff G, Jung EM. High resolution ultrasound including elastography and contrast-enhanced ultrasound (CEUS) for early detection and characterization of liver lesions in the humanized tumor mouse model. Clin Hemorheol Microcirc. 2012;52(2-4):93-106.
Erstpublikation "Humanisierte Tumormaus"
Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Männel DN, Ortmann O, Kroemer A, Brockhoff G. Humanized tumor mice - a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer. 2011 Nov 1;129(9):2194-206.
Vollmann-Zwerenz A, Diermeier-Daucher S, Wege AK, Sassen A, Schmidt-Brücken E, Hofstaedter F, Ortmann O, Nauwelaers F, Brockhoff G. Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry - possibilities and limitations. Cytometry A. 2010 Apr;77(4):387-98.
-
Brockhoff GListenelement Nr. 2
Glehr G, Kronenberg K, Arella F, Kapinsky M, Segundo D, Escudero MI, Xydia M, Veltman H, Hähnel V, Wenzel J, López Madrona VJ, Schlitt HJ, Geissler EK, Brockhoff G, Spang R, Martínez Cáceres E, López Hoyos M, Riquelme P, Hutchinson JA: Superior precision of clinical predictions after CD3-relativisation to align flow cytometry data. EBioMedicine. 2026 Aug 12;131:106427.
Fiedler M, Off A, Gärtner A, Brockhoff G, Eichberger J, Gottsauner M, Schuderer JG, Maurer M, Bauer RJ, Gerken M, Reichert TE, Ettl T, Weber F. Increased PD-1/PD-L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never-Smokers and Never-Drinkers. Head Neck. 2025 Mar;47(3):822-831.
Brockhoff G. Complementary tumor diagnosis by single cell-based cytogenetics using multi-marker fluorescence in-situ hybridization (mFISH). Curr Protoc. 2023 Nov;3(11):e942.
Brockhoff G. "Shedding" light on HER4 signaling in normal and malignant breast tissues. Cell Signal. 2022 Jul 9;97:110401.
Fiedler M, Schulz D, Piendl G, Brockhoff G, Eichberger J, Menevse AN, Beckhove P, Hautmann M, Reichert TE, Ettl T, Bauer RJ. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines. Exp Cell Res. 2020 Nov 1;396(1):112259.
Brockhoff G. Target HER four in breast cancer? Oncotarget. 2019 May 7;10(34):3147-3150.
Holzschuh MA, Czyz Z, Hauke S, Inwald EC, Polzer B, Brockhoff G. HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category. Histopathology. 2017 Oct;71(4):610-625.
Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstädter F, Gerstenhauer M, Brockhoff G, Ortmann O. 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. Breast Cancer Res Treat. 2015 Oct;153(3):647-58.
Krüger JM, Thomas M, Korn R, Dietmann G, Rutz C, Brockhoff G, Specht K, Hasmann M, Feuerhake F. Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy. Am J Pathol. 2013 Aug;183(2):336-43.
Diermeier-Daucher S, Ortmann O, Buchholz S, Brockhoff G. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 2009;11(4):R50..
Diermeier-Daucher S, Brockhoff G. Flow cytometric FRET analysis of ErbB receptor tyrosine kinase interaction. Curr Protoc Cytom. 2008 Jul;Chapter 12:Unit12.14.
Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci. 2008;1130:280-6.
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008;10(1):R2.
-
Wege AKListenelement Nr. 3
Lüttgenau SM, Emming C, Wagner T, Harms J, Guske J, Weber K, Neugebauer U, Schröter R, Panichkina O, Pethő Z, Weber F, Schwab A, Wege AK, Nedvetsky P, Krahn MP. Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6. Mol Cancer. 2021 May 4;20(1):74.
Dreyer TF, Kuhn S, Stange C, Heithorst N, Schilling D, Jelsma J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer. Cancer Immunol Res. 2021 Apr 27.
Bitterer F, Hornung M, Platz Batista da Silva N, Schlitt HJ, Stroszczynski C, Wege AK, Jung EM. In vivo detection of breast cancer liver metastases in humanized tumour mice using tumour specific contrast agent BR55®. Clin Hemorheol Microcirc. 2020;76(4):559-572.
Stripecke R, Münz C, Schuringa JJ, Bissig KD, Soper B, Meeham T, Yao LC, Di Santo JP, Brehm M, Rodriguez E, Wege AK, Bonnet D, Guionaud S, Howard KE, Kitchen S, Klein F, Saeb-Parsy K, Sam J, Sharma AD, Trumpp A, Trusolino L, Bult C, Shultz L. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med. 2020 Jul 7;12(7):e8662.
Walcher L, Hilger N, Wege AK, Lange F, Tretbar US, Blaudszun AR, Fricke S. Humanized mouse model: Hematopoietic stemcell transplantation and tracking using short tandem repeat technology. Immun Inflamm Dis. 2020 Sep;8(3):363-370.
Riquelme P, Haarer J, Kammler A, Walter L, Tomiuk S, Ahrens N, Wege AK, Goecze I, Zecher D, Banas B, Spang R, Fändrich F, Lutz MB, Sawitzki B, Schlitt HJ, Ochando J, Geissler EK, Hutchinson JA. TIGIT iTregs elicited by human regulatory macrophages control T cell immunity. Nat Commun. 2018 Jul 20;9(1):2858.
Wege AK. Humanized Mouse Models for the preclinical assessment of cancer immunotherapy. BioDrugs. 2018 Jun;32(3):245-266.
Ramos-Gomes F, Bode J, Sukhanova A, Bozrova SV, Saccomano M, Mitkovski M, Krueger JE, Wege AK, Stuehmer W, Samokhvalov PS, Baty D, Chames P, Nabiev I, Alves F. Single- and two-photon imaging of human micrometastases and disseminated tumour cells with conjugates of nanobodies and quantum dots. Sci Rep. 2018 Mar 15;8(1):4595.
Tsoneva D, Minev B, Frentzen A, Zhang Q, Wege AK, Szalay AA. Humanized Mice with subcutaneous human solid tumors for immune response analysis of vaccinia virus-mediated oncolysis. Mol Ther Oncolytics. 2017 Mar 21;5:41-61.
Kesselring R, Glaesner J, Hiergeist A, Naschberger E, Neumann H, Brunner SM, Wege AK, Seebauer C, Köhl G, Merkl S, Croner RS, Hackl C, Stürzl M, Neurath MF, Gessner A, Schlitt HJ, Geissler EK, Fichtner-Feigl S. IRAK-M expression in tumor cells supports c olorectal cancer progression through reduction of antimicrobial defense and stabilization of STAT3. Cancer Cell. 2016 May 9;29(5):684-696.